Drug Trial Radar · NCT05798117
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Feb 28, 2023
Primary completion
Sep 24, 2026
Study completion Sep 24, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
Conditions
- Systemic Lupus Erythematosus
- Lupus Nephritis
Interventions
YTB323Drug
Single infusion of YTB323
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with AEs and SAEsTime frame: Day 1 to 2 years
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Bern, Switzerland
Novartis Investigative Site
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.